Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota

International Journal of Antimicrobial Agents

Volumn 46, Issue 1, 2015, Pages 60-65

  Rashid, Mamun Ur ^a   Rosenborg, Staffan ^a   Panagiotidis, Georgios ^a   Löfdal, Karin Söderberg ^a   Weintraub, Andrej ^a   Nord, Carl Erik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Ceftazidime avibactam; Clostridium difficile; Human intestinal microbiota

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; CEFTAZIDIME;

ADULT; ADVERSE DRUG REACTION; AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTEROIDES; BIFIDOBACTERIUM; BIOASSAY; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM; CONTINUOUS INFUSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FECES LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCOCCUS; ESCHERICHIA COLI; FECES ANALYSIS; FEMALE; FLATULENCE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INTESTINE FLORA; LACTOBACILLUS; MACULOPAPULAR RASH; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; BACTERIUM; CHEMISTRY; CLASSIFICATION; DRUG EFFECTS; FECES; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MICROFLORA; NORMAL HUMAN; PLASMA; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADULT; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIA; CEFTAZIDIME; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HEALTHY VOLUNTEERS; HUMANS; MALE; MICROBIOTA; PLASMA; YOUNG ADULT;

EID: 84934993852     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.02.027     Document Type: Article

References (29)

1. Allocati N, Masulli M, Alexeyev M.F., Di Ilio C. Escherichia coli in Europe: an overview. Int J Environ Res Public Health 2013; 10:6235-54.
2. D'Agata EM. Rapidly rising prevalence of nosocomial multidrug-resistant, Gram-negative bacilli: a 9-year surveillance study. Infect Control Hosp Epidemiol 2004; 25:842-6.
3. Cosgrove SE, Kaye KS, Eliopoulous G.M., Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002; 162:185-90.
4. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant Gram-negative bacilli. Antimicrob Agents Chemother 2008; 52:813-21.
5. Curello J, MacDougall C. Beyond susceptible and resistant, part II: Treatment of infections due to Gram-negative organisms producing extended-spectrum β-lactamases. J Pediatr Pharmacol Ther 2014; 19:156-64.
6. Toussaint KA, Gallagher JC. β-Lactam/β-lactamase inhibitor combinations: from then to now. Ann Pharmacother 2015; 49:86-98.
7. Stachyra T, Levasseur P, Pechereau M.C., Girard AM, Claudon M, Miossec C, et al. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapen-emase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 2009; 64:326-9.
8. Lucasti C, Popescu I, Ramesh M.K., Lipka J., Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother 2013; 68:1183-92.
9. Vazquez JA, González Patzán LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 2012; 28: 1921-31.
10. Rashid MU, Weintraub A, Nord CE. Effect of new antimicrobial agents on the ecological balance of human microflora. Anaerobe 2012; 18:249-53.
11. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001; 1:101-14.
12. Sullivan Å, Edlund C, Nord CE. Interaction between antimicrobial agents and the oropharyngeal and intestinal microflora. In: Bryskier A, editor. Antimicrobial agents. Washington, DC: ASM Press; 2005. p. 1357-70.
13. Nord CE, Rasmanis G, Wahlund E. Effect ofdalbavancin on the normal intestinal microflora. J Antimicrob Chemother 2006; 58:627-31.
14. Heimdahl A, Nord CE. Effect of phenoxymethylpenicillin and clindamycin on the oral, throat and faecal microflora of man. Scand J Infect Dis 1979; 11: 233-42.
15. Rashid MU, Lozano HM, Weintraub A, Nord CE. In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden. Anaerobe 2013; 20:32-5.
16. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. In: Document M7-A9.9th ed Wayne, PA: CLSI; 2012.
17. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard. In: Document M11-A8. 8th ed. Wayne, PA: CLSI; 2012.
18. Nord CE, Edlund C. Impact of antimicrobial agents on human intestinal microflora. J Chemother 1990; 2:218-37.
19. Nord CE, Heimdahl A, Lundberg C., Marklund G. Impact of cefaclor on the normal human oropharyngeal and intestinal microflora. Scand J Infect Dis 1987; 19:681-5.
20. Takesue Y, Yokoyama T, Akagi S., Ohge H, Murakami Y, Sakashita Y., et al. Changes in intestinal flora after administration of panipenem/betamipron or sulbac-tam/cefoperazone for treatment of postoperative infections in gastrectomy patients. J Infect Chemother 1999; 5:52-7.
21. Kager L, Brismar B, Malmborg A.S., Nord CE. Impact of cefbuperazone on the colonic microflora in patients undergoing colorectal surgery. Drugs Exp Clin Res 1986; 12:983-6.
22. Arvidsson A, Alvan G, Angelin B., Borga O, Nord CE. Ceftriaxone: renal and biliary excretion and effect on the colon microflora. J Antimicrob Chemother 1982; 10:207-15.
23. Wilson SE, Nord CE. Clinical trials of extended spectrum penicillin/β-lactamase inhibitors in the treatment of intra-abdominal infections. European and North American experience. Am J Surg 1995; 169:21S-6S.
24. Richardson BL, Woodford JD, Andrews GD. The pharmacy of ceftazidime. J Antimicrob Chemother 1981; 8:233-6.
25. Labia R, Beguin-Billecoq R, Guionie M. Behaviour of ceftazidime towards β-lactamases. J Antimicrob Chemother 1981; 8:141-6.
26. Nord CE. Mechanisms of β-lactam resistance in anaerobic bacteria. Rev Infect Dis 1986; 8:543-8.
27. Knothe H, Dette GA, Shah PM. Impact of injectable cephalosporins on the gastrointestinal microflora: observations in healthy volunteers and hospitalized patients. Infection 1985; 13:129-33.
28. Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. IntJ Antimicrob Agents 2000; 16:5-15.
29. Spencer RC. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother 1998; 41:21-7.